EP2296762A1 - Verfahren zur ästhetischen behandlung von cellulitis-haut mit lipotomie und vorrichtung zur durchführung dieses verfahrens - Google Patents
Verfahren zur ästhetischen behandlung von cellulitis-haut mit lipotomie und vorrichtung zur durchführung dieses verfahrensInfo
- Publication number
- EP2296762A1 EP2296762A1 EP08805626A EP08805626A EP2296762A1 EP 2296762 A1 EP2296762 A1 EP 2296762A1 EP 08805626 A EP08805626 A EP 08805626A EP 08805626 A EP08805626 A EP 08805626A EP 2296762 A1 EP2296762 A1 EP 2296762A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- volume
- ultrasound
- hypotonic solution
- tissue
- osmolarity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 42
- 208000035484 Cellulite Diseases 0.000 title abstract description 13
- 206010049752 Peau d'orange Diseases 0.000 title abstract description 13
- 230000036232 cellulite Effects 0.000 title abstract description 13
- 238000002347 injection Methods 0.000 claims description 49
- 239000007924 injection Substances 0.000 claims description 49
- 239000000815 hypotonic solution Substances 0.000 claims description 36
- 238000002604 ultrasonography Methods 0.000 claims description 35
- 238000011282 treatment Methods 0.000 claims description 27
- 210000000577 adipose tissue Anatomy 0.000 claims description 26
- 210000001519 tissue Anatomy 0.000 claims description 25
- 206010007882 Cellulitis Diseases 0.000 claims description 6
- 238000011156 evaluation Methods 0.000 claims description 5
- 238000005259 measurement Methods 0.000 claims description 5
- 239000000523 sample Substances 0.000 claims description 4
- 230000002500 effect on skin Effects 0.000 claims description 3
- 230000010355 oscillation Effects 0.000 claims description 3
- 230000006835 compression Effects 0.000 claims description 2
- 238000007906 compression Methods 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 13
- 239000012528 membrane Substances 0.000 description 13
- 239000011734 sodium Substances 0.000 description 13
- 229910052708 sodium Inorganic materials 0.000 description 13
- 239000003925 fat Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 210000001789 adipocyte Anatomy 0.000 description 7
- 210000000170 cell membrane Anatomy 0.000 description 7
- 230000003204 osmotic effect Effects 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 238000009792 diffusion process Methods 0.000 description 6
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000010889 donnan-equilibrium Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 3
- 150000001450 anions Chemical class 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 206010033675 panniculitis Diseases 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 229940064804 betadine Drugs 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 210000004003 subcutaneous fat Anatomy 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010016803 Fluid overload Diseases 0.000 description 1
- 208000031856 Haemosiderosis Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000007379 Muscle Hypotonia Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 206010067868 Skin mass Diseases 0.000 description 1
- 206010040893 Skin necrosis Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000002357 osmotic agent Substances 0.000 description 1
- 238000009527 percussion Methods 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000036514 plasma sodium concentration Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000001173 tumoral effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H23/00—Percussion or vibration massage, e.g. using supersonic vibration; Suction-vibration massage; Massage with moving diaphragms
- A61H23/02—Percussion or vibration massage, e.g. using supersonic vibration; Suction-vibration massage; Massage with moving diaphragms with electric or magnetic drive
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H23/00—Percussion or vibration massage, e.g. using supersonic vibration; Suction-vibration massage; Massage with moving diaphragms
- A61H23/02—Percussion or vibration massage, e.g. using supersonic vibration; Suction-vibration massage; Massage with moving diaphragms with electric or magnetic drive
- A61H23/0245—Percussion or vibration massage, e.g. using supersonic vibration; Suction-vibration massage; Massage with moving diaphragms with electric or magnetic drive with ultrasonic transducers, e.g. piezoelectric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H7/00—Devices for suction-kneading massage; Devices for massaging the skin by rubbing or brushing not otherwise provided for
- A61H7/002—Devices for suction-kneading massage; Devices for massaging the skin by rubbing or brushing not otherwise provided for by rubbing or brushing
- A61H7/004—Devices for suction-kneading massage; Devices for massaging the skin by rubbing or brushing not otherwise provided for by rubbing or brushing power-driven, e.g. electrical
- A61H7/005—Devices for suction-kneading massage; Devices for massaging the skin by rubbing or brushing not otherwise provided for by rubbing or brushing power-driven, e.g. electrical hand-held
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H20/17—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/10—Characteristics of apparatus not provided for in the preceding codes with further special therapeutic means, e.g. electrotherapy, magneto therapy or radiation therapy, chromo therapy, infrared or ultraviolet therapy
- A61H2201/105—Characteristics of apparatus not provided for in the preceding codes with further special therapeutic means, e.g. electrotherapy, magneto therapy or radiation therapy, chromo therapy, infrared or ultraviolet therapy with means for delivering media, e.g. drugs or cosmetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2207/00—Anti-cellulite devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0004—Applications of ultrasound therapy
- A61N2007/0008—Destruction of fat cells
Definitions
- the invention relates to a method of aesthetic treatment of cellulitis skin by lipotomy, and to a device for the implementation of this method.
- the invention falls within the field of superficial cosmetic skin treatments.
- cellulite skin or “cellulite”, used in the sense of the present invention, refer exclusively to an aesthetic cellulite that causes dents called “orange peel” on the skin. This unsightly “padded” appearance of the skin is due to a very localized hypertrophy of subcutaneous adipose tissue resulting from fat storage.
- the subcutaneous adipose tissue is composed of cells, in particular adipocytes.
- Lipotomy is a method of aesthetic treatment of cellulitic skin whose purpose is to weaken the membrane of adipocytes and ultimately obtain the lysis of this membrane and the destruction of adipocytes.
- the weakening of the cell membranes is obtained by the entry of solvent into the interior of the adipocytes following the induction of an osmotic pressure difference on either side of said membranes.
- osmole is a physical unit for measuring osmotic pressure expressed in moles per liter.
- Osm osmole
- the osmotic pressure corresponds to the difference of the osmotic values on both sides of a semi-permeable membrane by two liquids not having the same richness in dissolved osmotically active molecules.
- Osmolarity is the concentration of dissolved substances in osmotic potency relative to molecular weight, and is also expressed in osmoles. It can be considered that the osmolarity of diffusible electrolytes of the intracellular and extracellular sectors is about 300 mOsm.
- the cell membrane is assimilated to a semipermeable membrane.
- intra-fat administration of a hypotonic solution that is to say a solution whose osmolarity is clearly lower than that of the intracellular medium.
- a flow of solvent in this case water, enters the adipocytes creating a rapid increase in intracellular volume and a thinning of the cytoplasmic membrane, leading to the embrittlement of this cell membrane up to at his break.
- solvent in this case water
- it involves inducing cell destruction that controls the hypo osmolarity caused by the treatment by virtue of safety and efficacy parameters.
- This treatment is applicable to all types of tissue: fatty, cellulitic and tumoral. In the case of cellulite or greasy tissue, the treatment is associated with ultrasound and incidentally with vibrations then taking the name of lipotomy.
- Lipotomy is a technique that, at its origins, could give rise to serious accidents such as tissue and skin necrosis. These accidents generally resulted from an overdose during the administration of the hypotonic fluids used. Although it is now better controlled, the results obtained can nevertheless sometimes show a lack of reproducibility according to the patients and the treated areas.
- the phenomena of osmosis begin to cause the rupture of the cell membranes from a threshold value which is called the "threshold of hypo osmolarity". Moreover, the rupture of the membranes becomes complete below a value which is known as the "limit value".
- the cell membrane of red blood cells serves as a model for all other cells.
- Tests assessing the threshold value and the limit value are part of the general nomenclature of laboratory tests that assess the resistance of red blood cells to hypo osmolarity in order to search for abnormal brittleness.
- the hypo osmolarity or hypotonia of these media in vitro is achieved by a dilution of sodium chloride.
- the osmolar media consist of water for injection as a solvent and sodium chloride as the solute.
- the physiological medium is represented by a solute of 9 grams per liter of solvent.
- the threshold value is reached from 5 grams per liter of sodium chloride and the limit value from 3 grams per liter of sodium chloride.
- the methods of treatment of fatty tissues can be classified in three groups thanks to the following model: i) Group 1: Ineffective treatments, ie carried out at an osmolarity higher than the threshold value, ii) Group 2: Partially effective treatments, ie carried out at a osmolarity between the threshold value and the limit value, and finally iii) Group 3: Totally effective treatments, ie carried out at an osmolarity lower than the limit value.
- Treatments of fatty tissue or cellulitis will seek partial effectiveness while the treatment of cancerous tumors should be of total effectiveness.
- the mode of action acts by osmolar difference between the cell and its environment. This difference is called the "osmolar gradient”.
- GO Osmolarity of the physiological medium (g / 1) - Threshold value (g / 1)
- the osmolar gradient of the threshold value is equal to 9-5, ie 4 g / l.
- the osmolar gradient of the limit value is equal to 9 - 3, ie 6 g / l.
- the partial efficiency is obtained for an osmolar gradient ranging from 4 to 6 grams per liter of sodium chloride solute.
- the total efficiency is obtained from an osmolar gradient greater than or equal to 6 grams per liter of sodium chloride solute.
- the problem is to transpose in vivo in humans the known data in vitro.
- it is absolutely not easy to precisely determine the volume of hypotonic solution to be injected and / or its osmolarity depending on the area of fatty tissue to be treated, which leads to the disadvantages described above.
- the present invention therefore aims to improve the method of aesthetic treatment of the cellulite skin that is lipotomy, particularly in terms of safety and reproducibility, while obtaining optimal efficiency.
- the invention relates to a method for aesthetically treating the cellulitis skin of a patient by lipotomy, characterized in that it comprises at least the following steps:
- Eo is the ultrasound thickness of said fatty tissue at rest
- E p is the ultrasound thickness of said fat tissue compressed to the maximum
- the ultrasound thickness at rest corresponds to the thickness of the hypodermis from the surface of the skin to the muscle membrane (thickness at rest).
- the ultrasound thickness of the maximum compressed tissue corresponds to the thickness of the hypodermis from the surface of the skin to the muscle membrane measured under pressure, for example by pressing the skin with an ultrasound probe.
- the decrease in the thickness of the subcutaneous tissue is initially proportional to the pressure exerted, then, when this pressure reaches a significant value, the thickness of the compressed tissue remains constant regardless of the subsequent increase in pressure.
- a sufficient pressure is therefore applied until a constant compressed tissue thickness value is obtained.
- the calculation of the index IB is carried out by software which determines, from the ultrasound data measured in said steps 2) and 3), at least one of the following parameters: injection mode of the hypotonic solution, ie the injection angle
- the volume of hypotonic solution to be injected is equal to or proportional to the volume of tissue of the zone to be treated.
- the method further comprises an additional step in which the software calculates the osmolarity of the initial interstitial area of the patient from the results of an ionogram.
- This examination consists in determining the plasma concentrations of ions sodium, potassium, calcium, magnesium, chlorine, bicarbonate, as well as the plasma concentrations in proteins and in sugar (Blood sugar).
- the Gibbs-Donnan effect also known as Donnan effect, Doniian's law, or Gibbs-Donnan equilibrium
- This model is applied to the vascular and interstitial sector.
- the vascular sector contains non-diffusible proteins and anions.
- the initial osmolarity of the interstitial sector is equal to the intracellular osmolarity.
- the initial osmolarity of the interstitial sector (B) can be calculated by applying the second Gibbs-Donnan law concerning the equality of the products of the osmolarities of the diffusible anions by the osmolarity of the diffusible cations between the vascular and interstitial compartments.
- the amount of initial solute in milliosmol is given by the following formula (2): Where A is the volume of the initial interstitial sector (expressed in milliliters) and B is the initial osmolarity of the interstitial sector (expressed in milliosmoles / liter).
- Partially effective GO B - H (4)
- the final sodium osmolarity (K) is equal to the sum of the initial amount of sodium in the interstitial area and the amount of sodium injected, all divided by the final volume A + D then multiplied by one thousand.
- the safety index for the aesthetic treatment of fat and cellulite clusters will therefore preferably remain below 55%, keeping a safety margin of 10%.
- the final interstitial hypo osmolarity to be reached in the interstitial sector (H) corresponds to the difference between the initial osmolarity of the interstitial sector (B) and the osmolar gradient to be applied.
- This osmolar gradient is expressed in milli osmoles per liter and in the case of the treatment of cellulite, it will correspond to the values of the osmolar gradient of partial efficiency previously defined.
- the software uses the initial volume of the interstitial sector (A) expressed in milliliters, the initial interstitial sector posmolarity (B) expressed in milli osmoles per liter and the final interstitial hypo osmolarity to be reached (H) in milli osmoles per liter. It is then possible to define:
- D corresponding to the volume of hypotonic solution to be injected
- E corresponding to the osmolarity of the hypotonic solution to be injected
- D is chosen to be equal to the total tissue volume so as to consider the injection as having instantaneous diffusion in A.
- This volume corresponds to a cylinder of length equal to that of the Injection needle and radius called scattering ray.
- the injections being spaced in regular and parallel ways, there is a relationship between the spacing, the needle length, the thickness of the hypodermis at rest, the injection angle and the diffusion radius allowing the cylinders to to be contiguous.
- the volume of the initial interstitial sector A is calculated by the software from the ultrasound data by applying the formula (1) described above (Bernstein index).
- the destruction of the fatty tissue is promoted by the action of ultrasound on the already weakened tissue after administration of said hypotonic solution.
- the lysis of the hyperhydrated adipocytes is thus more easily obtained by causing the destruction of the cell membranes.
- the method according to the invention then further comprises a step of applying ultrasound.
- ultrasound it is preferred to use low frequency ultrasound. Their destructive effects have been attributed to a mechanism of contact cavitation or a simple acoustic tension on weakened membranes.
- the ultrasonic radiation power that can be received by the skin is limited because of the cutaneous tolerance to 3 watts on average per cm 2 of skin.
- the application of higher powers over shorter time ranges is preferably implemented, in order to achieve larger and more effective instantaneous powers.
- an emission time of 0.2 seconds followed by 0.2 seconds of silence allows the application of ultrasonic waves with a power of 6 Watts / cm while respecting the average 3 Watts per cm. 2 tolerated.
- the powers used can reach up to 24 Watts / cm 2 .
- the method according to the invention further comprises a step of applying vibrations to the determined zone. This step is performed on the infiltrated tissues after the injections of the hypotonic solution (draining vibrations).
- the first lipotomies gave rise to undesirable effects such as cutaneous hemosiderosis, the presence of residual fatty nodules or a collection of triglycerides. These are eliminated or greatly reduced by the application of vertical draining vibrations allowing the release of a portion of the injected solution mixed with debris.
- the vibrations are applied perpendicularly to the plane formed by the cutaneous surface.
- the mechanical vibrations are easily transmitted in depth and thus allow optimal drainage of the infiltrated area.
- the power of the apparatus is advantageously between 112 and 450 Watts, preferably 225 Watts.
- a vibration frequency around 12,000 oscillations or a reciprocating cycle per minute with an amplitude of vibratory motion between 0.5 and 2 mm has been found to be the most effective in causing a large outflow of the administered hypotonic solution. .
- Another object of the invention is therefore a device for the aesthetic treatment of cellulitic skin by dermal injection of at least one hypotonic solution into a determined area of fatty tissue to be treated (lipotomy), characterized in that it comprises:
- At least one ultrasound generating device At least one ultrasound generating device
- At least one ultrasound probe capable of measuring the thickness of said fatty tissue at rest and in maximum compression within said zone
- At least one data processing software in particular able to calculate the percentage (IB or Bernstein index) represented by the volume of the extracellular sector of said tissue within said zone according to the following equation (1): in which :
- said device further comprises at least one apparatus generating vibrations perpendicular to the cutaneous surface of said fatty tissue (called vibro-drainer).
- the vibrations applied by this device preferably have a frequency around 12,000 oscillations or cycles per minute.
- the software integrated within this device also calculates, from the ultrasound data, at least one of the following parameters:
- the mode of injection of the hypotonic solution i.e. the angle of injection and the spacing between two injection points, the osmolarity of the hypotonic solution to be administered
- the device further comprises a computer system for controlling and automatically delivering injections of the hypotonic solution whose volume is directly deduced from the ultrasound measurements.
- the ultra sounds are low frequencies and their mode of work allows to deliver instantaneous power of 3 to 24 Watts / square cm while respecting an average power of 3
- FIG. 1 represents a sectional diagram of an area of fatty tissue to be treated on which the hypodermic thickness, the spacing between two injection points, the length of the injection needle, the double of the scattering radius and the injection angle
- FIGS. 2 and 3 are graphs giving the efficacy results of a comparative study of the efficacy of lipotomy treatments of fatty tissues according to methods that are not in accordance with FIG. invention. On these graphs, efficiency and lack of efficiency are functions of the osmolar gradients used.
- EXAMPLE 1 COMPARATIVE CLINICAL STUDY ACCORDING TO A CLASSIC LIPOTOMY METHOD NOT PART OF THE INVENTION
- Each subject was photographed from the front, in profile and the circumference of the area to be treated was measured.
- the areas were then drawn in pencil showing a major axis and a width.
- the injection points were spaced every centimeter in the width direction and to a variable extent between 1 cm and 5 cm in the lengthwise direction depending on the fat tissue thickness.
- the thickness of fatty tissue was then measured by an ultrasound probe, at the level of the maximum thickness and the minimum thickness of the area to be treated, and at rest and in a compressed position. Ultrasound measurements and biological analysis results were captured by treatment software.
- the osmolarity gradients applied ranged from 99 milliliters per liter to 170 milliliters and the interstitial osmolarity coefficient of sodium was calculated by always keeping it below 55%.
- the strips and the ultrasonic heads were sterilized by soaking in a cold sterilization bath.
- the treatment flasks were hooked to a gallows while the injection equipment was resting on a sterile field.
- the vibro-draining apparatus was placed in a sterile envelope.
- the first dermo-epidermal injections were first performed in order to anesthetize each point using the 0.3 / 13 needles and the hypotonic treatment solution cooled to 5 ° C. Then the hypotonic solution was injected with 0.8 / 50 needles according to the software information and filling the syringe with the three-way stopcock.
- a garment of contention was worn by each subject for one month during the day only.
- EXAMPLE 2 HIGHLIGHTING THE IMPORTANCE OF THE INJECTION ANGLE
- Example 2 The results of the study presented above in Example 1 were repeated by eliminating all the oblique injections performed without indication of injection angle and retaining only injections perpendicular to the cutaneous surface. The results obtained are shown in the appended FIG. 3 on which the efficiency or the inefficiency of the method is given according to the different osmolar gradients used.
- the efficiency range of the osmolar gradient is relatively low, about 10 milliosmoles / liter, which gives importance to the ionogram evaluating the initial interstitial osmolarity since it is likely to vary. the gradient of 13 milliosmoles / liter as we saw above in Example 1.
- the method according to the invention improves the current lipotomy method, in particular its reproducibility and its safety. implementation provided that a strict parameter setting is respected.
- lipotomy is a good alternative to lipo aspiration.
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Rehabilitation Therapy (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Primary Health Care (AREA)
- Medicinal Chemistry (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/FR2008/000736 WO2009144389A1 (fr) | 2008-05-30 | 2008-05-30 | Methode de traitement esthetique de la peau cellulitique par lipotomie et dispositif pour la mise en oeuvre de cette methode |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2296762A1 true EP2296762A1 (de) | 2011-03-23 |
Family
ID=40386435
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP08805626A Withdrawn EP2296762A1 (de) | 2008-05-30 | 2008-05-30 | Verfahren zur ästhetischen behandlung von cellulitis-haut mit lipotomie und vorrichtung zur durchführung dieses verfahrens |
Country Status (3)
Country | Link |
---|---|
US (1) | US8328722B2 (de) |
EP (1) | EP2296762A1 (de) |
WO (1) | WO2009144389A1 (de) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102096204B1 (ko) * | 2019-05-31 | 2020-04-02 | 최명석 | 국소지방 파괴 방법 및 국소지방 파괴용 저장성 용액 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4183249A (en) * | 1975-03-07 | 1980-01-15 | Varian Associates, Inc. | Lens system for acoustical imaging |
DE3788757D1 (de) * | 1986-08-20 | 1994-02-24 | Siemens Ag | Verfahren und Einrichtung zur adaptiven Fokussierung bei einem medizinischen Ultraschall-Bildgabegerät. |
US5208747A (en) * | 1988-04-07 | 1993-05-04 | John Wilson | Ultrasonic scanning method and apparatus for grading of live animals and animal carcases |
US5031627A (en) * | 1989-10-17 | 1991-07-16 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Method and apparatus for characterizing reflected ultrasonic pulses |
CA2126088C (en) * | 1991-12-19 | 1999-05-11 | Royden James William Lake | Fat depth measuring apparatus |
US5419761A (en) * | 1993-08-03 | 1995-05-30 | Misonix, Inc. | Liposuction apparatus and associated method |
US5941825A (en) * | 1996-10-21 | 1999-08-24 | Philipp Lang | Measurement of body fat using ultrasound methods and devices |
CA2300843A1 (en) * | 1997-08-19 | 1999-02-25 | Philipp Lang | Measurement of capillary related interstitial fluid using ultrasound methods and devices |
US6190315B1 (en) * | 1998-01-08 | 2001-02-20 | Sontra Medical, Inc. | Sonophoretic enhanced transdermal transport |
US6013031A (en) * | 1998-03-09 | 2000-01-11 | Mendlein; John D. | Methods and devices for improving ultrasonic measurements using anatomic landmarks and soft tissue correction |
US6030374A (en) | 1998-05-29 | 2000-02-29 | Mcdaniel; David H. | Ultrasound enhancement of percutaneous drug absorption |
US6358208B1 (en) * | 1998-11-21 | 2002-03-19 | Philipp Lang | Assessment of cardiovascular performance using ultrasound methods and devices that interrogate interstitial fluid |
DE19904907C2 (de) * | 1999-02-06 | 2003-03-27 | Rudolf Weyergans | Verfahren zur lokalen Verminderung von Fett- und Stoffwechselschlackenaufspeicherungen zur Verbesserung der körperlichen Erscheinung bei Cellulite |
US6318146B1 (en) * | 1999-07-14 | 2001-11-20 | Wisconsin Alumni Research Foundation | Multi-imaging modality tissue mimicking materials for imaging phantoms |
US6524250B1 (en) * | 2000-09-19 | 2003-02-25 | Pearl Technology Holdings, Llc | Fat layer thickness mapping system to guide liposuction surgery |
JP4367410B2 (ja) * | 2003-02-18 | 2009-11-18 | パナソニック電工株式会社 | 内臓脂肪計測装置、プログラム、及び記録媒体 |
US20050096682A1 (en) * | 2003-11-05 | 2005-05-05 | Visibelle Derma Institute, Inc. | Vibratory blade device for body treatments |
FR2876907B1 (fr) * | 2004-10-27 | 2007-02-23 | Serge Bernstein | Solutions aqueuses pour la reduction de tissus graisseux |
US20060206040A1 (en) | 2005-03-09 | 2006-09-14 | Greenberg Ronald A | aparatus and method of body contouring and skin conditioning using a mobile suction device |
-
2008
- 2008-05-30 US US12/995,329 patent/US8328722B2/en not_active Expired - Fee Related
- 2008-05-30 EP EP08805626A patent/EP2296762A1/de not_active Withdrawn
- 2008-05-30 WO PCT/FR2008/000736 patent/WO2009144389A1/fr active Application Filing
Non-Patent Citations (1)
Title |
---|
See references of WO2009144389A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO2009144389A1 (fr) | 2009-12-03 |
US8328722B2 (en) | 2012-12-11 |
US20110166452A1 (en) | 2011-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Karim et al. | Indeterminate-depth burn injury—exploring the uncertainty | |
Lee et al. | Microdermabrasion as a novel tool to enhance drug delivery via the skin: an animal study | |
Scuderi et al. | Comparative evaluation of traditional, ultrasonic, and pneumatic assisted lipoplasty: analysis of local and systemic effects, efficacy, and costs of these methods | |
Selim et al. | Confocal microscopy study of nerves and blood vessels in untreated and treated port wine stains: preliminary observations | |
Nassar et al. | A randomized, controlled clinical study to investigate the safety and efficacy of acoustic wave therapy in body contouring | |
Shokeir et al. | Efficacy of pulsed dye laser versus intense pulsed light in the treatment of striae distensae | |
US20070179365A1 (en) | Method for monitoring body fluids | |
Liao et al. | Efficacy of combined ultrasound-and-microbubbles-mediated diclofenac gel delivery to enhance transdermal permeation in adjuvant-induced rheumatoid arthritis in the rat | |
Van Der Lugt et al. | A multicenter study of cellulite treatment with a variable emission radio frequency system | |
Feiszthuber et al. | Cavitation-enhanced delivery of insulin in agar and porcine models of human skin | |
Meyerholz et al. | Morphological parameters for assessment of burn severity in an acute burn injury rat model | |
Polat et al. | Application of the aqueous porous pathway model to quantify the effect of sodium lauryl sulfate on ultrasound-induced skin structural perturbation | |
Kline‐Schoder et al. | Ultrasound‐Enhanced Drug Delivery for Treatment of Onychomycosis | |
EP2296762A1 (de) | Verfahren zur ästhetischen behandlung von cellulitis-haut mit lipotomie und vorrichtung zur durchführung dieses verfahrens | |
Damestani et al. | Optical clearing agent perfusion enhancement via combination of microneedle poration, heating and pneumatic pressure | |
JP2022508645A (ja) | 皮下脂肪層を処置する方法 | |
JP5354155B2 (ja) | たるみ改善効果の提示方法 | |
Liao et al. | Efficacy of ultrasound mediated microbubbles in diclofenac gel to enhance transdermal permeation in rheumatoid arthritis induced rat | |
BE1017986A3 (fr) | Procede de mesure de la masse grasse et de la masse maigre d'un individu. | |
US20060233893A1 (en) | Aqueous solutions for the reduction of fatty tissue | |
Daftardar et al. | Ultrasound-mediated topical delivery of econazole nitrate with potential for treating Raynaud's phenomenon | |
Savoia et al. | Noninvasive body contouring by low frequency ultrasound: a clinical study | |
Sheng et al. | A single-blind study evaluating the efficacy of gold nanoparticle photothermal-assisted liposuction in an ex vivo human tissue model | |
Juch et al. | Home-Use Hyaluronic Acid Jet Injectors: Unreliable and Unsafe | |
Atif et al. | Oxygen saturation and blood volume analysis by photoacoustic imaging to identify pre and post-PDT vascular changes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20101230 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA MK RS |
|
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20131203 |